Given the striking anti‐tumor effects on HCC cells and hepatoma xenografts, the LRP1 β∆‐chain, an endogenous short peptide, may be a promising anti‐cancer agent with an optimal safety profile and high tolerability for use in patients with HCC. Here, LRP1 is linked to hepatocellular carcinoma.